The Effects of Celecoxib on High-sensitivity C-reactive Protein, D-dimer, von Willebrand Factor and Troponin-T in Continuous Ambulatory Peritoneal Dialysis Patients.
- Author:
Sang Hyun KIM
1
;
Su Hee KIM
;
Eun kyung LEE
;
Jai Won CHANG
;
Soon Bae KIM
;
Sang Koo LEE
;
Jung Sik PARK
Author Information
1. Department of Internal Medicine, College of Medicine, University of Ulsan, Seoul, Korea. sbkim@amc.seoul.kr
- Publication Type:Original Article ; Randomized Controlled Trial
- Keywords:
Celecoxib;
High sensitivity C-reactive protein;
CAPD
- MeSH:
Animals;
Atherosclerosis;
C-Reactive Protein*;
Cyclooxygenase 2 Inhibitors;
Humans;
Inflammation;
Peritoneal Dialysis, Continuous Ambulatory*;
Prospective Studies;
Prostaglandin-Endoperoxide Synthases;
Troponin T*;
von Willebrand Factor*;
Celecoxib
- From:Korean Journal of Nephrology
2004;23(2):309-317
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: It has become clear that inflammation is an important process in the pathogenesis of atherosclerosis. Cyclooxygenase (COX)-2 inhibitors, such as rofecoxib or celecoxib, are new nonsteroidal anti-inflammatory drugs. Some reports that COX-2 inhibitors decreased inflammatory markers in animals and humans. In this study, we evaluated the effects of celecoxib on the level of high-sensitivity C-reactive protein (hs-CRP), D-dimer, von Willebrand factor (vWF) and troponin-T in continuous ambulatory peritoneal dialysis (CAPD) patients. METHODS: From June 2002 to December 2002, 46 CAPD patients with hs-CRP equal or greater than 0.25 mg/dL were included in this prospective study. The 46 patients were randomized to the treatment group who took 200 mg of celecoxib daily for 4 weeks or to the control group who did not take the medication. Of the 46 patients, 43 patients completed this study. RESULTS: Baseline values of all the parameters were not significantly different between the two group. In the control group (N=22), the levels of hs- CRP, albumin, D-dimer, vWF and troponin-T did not change. In the treatment group (N=21), administration of celecoxib for 4 weeks significantly reduced hs-CRP from 0.77 (range 0.25-7.08) to 0.39 mg/dL (range 0.11-5.22, p<0.05). The level of albumin, D- dimer, vWF and troponin-T levels were not affected by the administration of celecoxib.0.CONCIUSION: Our preliminary short-term study shows that celecoxib decreased hs-CRP and not changed the level of vWF, D-dimer and torponin-T in CAPD patients. We suggest that celecoxib has an anti-inflammatory effect in usual dosage in CAPD patients.
